When did Oncobiologics IPO?

Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

What other stocks do shareholders of Oncobiologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP) , Network-1 Technologies (NTIP) , Allena Pharmaceuticals (ALNA) , Intra-Cellular Therapies (ITCI) , Cidara Therapeutics (CDTX) , Neuralstem (CUR) and Exelixis (EXEL) .

NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.19
▼
$8.65
50-Day Range: $0.72
▼
$7.40
52-Week Range: $0.57
▼
$1.53

Volume: 249,848 shs
Average Volume: 69,024 shs
Market Capitalization: $602.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Trends

Get Oncobiologics alerts:

Ad Porter & Company

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

About Oncobiologics Stock (NASDAQ:ONS)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Ad Porter & Company

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

ONS Stock News Headlines

August 2, 2023 | mirror.co.uk

BBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur final

July 30, 2023 | mirror.co.uk

Ons Jabeur ‘kicked off’ Wimbledon centre court moments before women’s final

July 26, 2024 | Crypto Swap Profits (Ad)

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

April 27, 2023 | nytimes.com

Are Away Carry-Ons Worth the Hype?

October 5, 2022 | dailymail.co.uk

ONS - the Office of National Statistics

See More Headlines

Receive ONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ONS
Previous Symbol: NYSE:ONS
CUSIP: N/A
CIK: 1649989
Web: www.oncobiologics.com
Phone: (609) 619-3990
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,840,000.00
Net Margins: -464.47%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -93.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.41

Sales & Book Value

Annual Sales: $3.81 million
Price / Sales: 158.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.36) per share
Price / Book: -6.13

Miscellaneous

Outstanding Shares: 72,200,000
Free Float: N/A
Market Cap: $602.15 million
Optionable: Not Optionable
Beta: -0.27

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Lawrence A. Kenyon
President, CEO, CFO, Secretary & Treasurer
Terry Dagnon
Chief Operating Officer
Jennifer M. Kissner
Senior Vice President-Clinical Development
Jeff Evanson
Chief Commercial Officer

Key Competitors

View All Competitors

ONS Stock Analysis - Frequently Asked Questions

When did Oncobiologics IPO?: Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.
What other stocks do shareholders of Oncobiologics own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL).